Unnamed: 0,title,date,stock,sentiment
314560.0,"CytoSorbents Awarded $2,897,172 Phase III STTR Contract To Advance HemoDefend-BGA Plasma And Whole Blood Filter To Clinical Trials",2020-06-09 07:09:00-04:00,CTSO,positive
314561.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,CTSO,neutral
314562.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-12 10:41:00-04:00,CTSO,neutral
314563.0,"CytoSorbents Announces CytoSorb Is Now EU Approved To Remove Rivaroxaban, A Leading Factor Xa Inhibitor And Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery",2020-05-12 07:11:00-04:00,CTSO,positive
314564.0,"The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda",2020-05-08 07:59:00-04:00,CTSO,neutral
314565.0,"Cramer Shares His Thoughts On DraftKings, Wells Fargo And More",2020-05-08 07:52:00-04:00,CTSO,positive
314566.0,Stocks That Hit 52-Week Highs On Thursday,2020-05-07 10:33:00-04:00,CTSO,neutral
314567.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,CTSO,negative
314568.0,66 Biggest Movers From Yesterday,2020-05-07 05:52:00-04:00,CTSO,neutral
314569.0,58 Stocks Moving In Wednesday's Mid-Day Session,2020-05-06 13:19:00-04:00,CTSO,neutral
314570.0,Stocks That Hit 52-Week Highs On Wednesday,2020-05-06 10:43:00-04:00,CTSO,neutral
314571.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,CTSO,positive
314572.0,CytoSorbents shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.,2020-05-06 08:22:00-04:00,CTSO,positive
314573.0,"B. Riley FBR Maintains Buy on CytoSorbents, Raises Price Target to $16",2020-05-06 07:44:00-04:00,CTSO,neutral
314574.0,"H.C. Wainwright Maintains Buy on CytoSorbents, Raises Price Target to $14",2020-05-06 07:33:00-04:00,CTSO,neutral
314575.0,"CytoSorbents Q1 EPS $(0.100) Beats $(0.130) Estimate, Sales $8.707M Beat $7.000M Estimate",2020-05-05 16:36:00-04:00,CTSO,neutral
314576.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,CTSO,positive
314577.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,CTSO,neutral
314578.0,CytoSorbents Reports $1.1M In Non-Dilutive Funding From New Jersey Business Tax Certificate Transfer Program,2020-04-29 07:18:00-04:00,CTSO,neutral
314579.0,"The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update",2020-04-28 07:36:00-04:00,CTSO,neutral
314580.0,Stocks That Hit 52-Week Highs On Monday,2020-04-27 10:21:00-04:00,CTSO,neutral
314581.0,FDA Grants Breakthrough Designation To CytoSorb For Removal Of Ticagrelor During Cardiopulmonary Bypass In Emergent And Urgent Cardiothoracic Surgery,2020-04-20 06:59:00-04:00,CTSO,positive
314582.0,CytoSorbents Highlights Recently Published Study Showing CytoSorb 'Improves Clinical Outcomes in Pneumonia Patients With Septic Shock and Acute Respiratory Distress Syndrome (ARDS) on ECMO',2020-04-15 07:03:00-04:00,CTSO,negative
314583.0,"The Daily Biotech Pulse: Amarin Reports Strong Q1 Vascepa Sales, BeiGene Aces Late-Stage Lung Cancer Study, Glaxo, Sanofi Strike COVID-19 Vaccine Partnership",2020-04-14 07:59:00-04:00,CTSO,negative
314584.0,86 Biggest Movers From Yesterday,2020-04-14 05:19:00-04:00,CTSO,negative
314585.0,63 Stocks Moving In Monday's Mid-Day Session,2020-04-13 12:35:00-04:00,CTSO,neutral
314586.0,Stocks That Hit 52-Week Highs On Monday,2020-04-13 10:25:00-04:00,CTSO,neutral
314587.0,CytoSorbents shares are trading higher after the company was granted emergency use authorization by the FDA for its CytoSorb to treat coronavirus.,2020-04-13 07:59:00-04:00,CTSO,positive
314588.0,US FDA Grants CytoSorb Emergency Use Authorization For Use In Patients With COVID-19 Infection,2020-04-13 07:45:00-04:00,CTSO,negative
314589.0,20 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-04-13 07:39:00-04:00,CTSO,neutral
314590.0,30 Stocks Moving in Monday's Pre-Market Session,2020-04-13 06:56:00-04:00,CTSO,neutral
314591.0,"CytoSorbents Highlights CEO Will Discuss Coronavirus Outbreak, Co.'s CytoSorb Treatment Of Cytokine Storm During Cowen's Coronavirus Series Call Fri.",2020-04-03 12:08:00-04:00,CTSO,neutral
314592.0,77 Biggest Movers From Yesterday,2020-04-01 04:31:00-04:00,CTSO,neutral
314593.0,CytoSorb Receives Marketing Approval In Mexico With Commercialization To Commence With Partner Fresenius Medical Care,2020-03-31 07:10:00-04:00,CTSO,positive
314594.0,88 Biggest Movers From Yesterday,2020-03-26 04:07:00-04:00,CTSO,neutral
314595.0,Mid-Afternoon Market Update: Dow Surges 1100 Points; Astrotech Shares Spike Higher,2020-03-25 14:35:00-04:00,CTSO,positive
314596.0,62 Stocks Moving In Wednesday's Mid-Day Session,2020-03-25 12:16:00-04:00,CTSO,neutral
314597.0,Mid-Day Market Update: Dow Jumps Over 500 Points; Immutep Shares Plummet,2020-03-25 12:11:00-04:00,CTSO,positive
314598.0,20 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-03-25 07:35:00-04:00,CTSO,neutral
314599.0,CytoSorbents Says CytoSorb Has Been Used In More Than 70 Coronavirus Patients To 'help treat cytokine storm and life-threatening complications such as acute respiratory distress syndrome',2020-03-25 07:21:00-04:00,CTSO,positive
314600.0,100 Biggest Movers From Friday,2020-03-09 05:25:00-04:00,CTSO,neutral
314601.0,60 Stocks Moving In Friday's Mid-Day Session,2020-03-06 12:11:00-05:00,CTSO,neutral
314602.0,CytoSorbents Q4 Sales $7.4M Beat $6.8M Estimate,2020-03-05 16:24:00-05:00,CTSO,neutral
314603.0,140 Biggest Movers From Friday,2020-03-02 04:43:00-05:00,CTSO,neutral
314604.0,86 Stocks Moving In Friday's Mid-Day Session,2020-02-28 12:19:00-05:00,CTSO,negative
314605.0,CytoSorbents Reports Shipment Arrives In Designated Mainland China Hospitals to Treat Cytokine Storm in Critically-ill Patients with COVID-19 Coronavirus Infection,2020-02-28 07:10:00-05:00,CTSO,positive
314606.0,25 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-02-19 08:10:00-05:00,CTSO,neutral
314607.0,CytoSorbents Enters Agreement With China Medical System Holdings Limited To Bring CytoSorb To Mainland China To Treat Critically-Ill Patients With COVID-19 Coronavirus Infection,2020-02-19 07:17:00-05:00,CTSO,positive
314608.0,2 Medical Devices Stocks Moving In Wednesday's Pre-Market Session,2020-01-29 07:44:00-05:00,CTSO,neutral
314609.0,12 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-01-29 07:41:00-05:00,CTSO,neutral
314610.0,CytoSorbents Announces EU Regulatory Approval And CE Mark Label Expansion For CytoSorb,2020-01-29 07:27:00-05:00,CTSO,positive
314611.0,43 Healthcare Stocks Moving In Tuesday's After-Market Session,2020-01-28 23:40:00-05:00,CTSO,neutral
314612.0,25 Medical Devices Stocks Moving In Tuesday's Session,2020-01-28 12:48:00-05:00,CTSO,neutral
314613.0,46 Stocks Moving In Tuesday's Mid-Day Session,2020-01-28 11:50:00-05:00,CTSO,neutral
314614.0,10 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-01-28 07:37:00-05:00,CTSO,neutral
314615.0,CytoSorbents Highlights Publication In The Lancet That 'provide the rationale to potentially use CytoSorb' As A Coronavirus Treatment,2020-01-28 07:06:00-05:00,CTSO,neutral
314616.0,CytoSorbents Sees Prelim. Q4 Sales $7.4M,2020-01-14 09:31:00-05:00,CTSO,neutral
314617.0,Stocks That Hit 52-Week Lows On Friday,2019-12-06 12:04:00-05:00,CTSO,negative
314618.0,UPDATE: CytoSorbents Says Data Monitoring Committee Recommended Co. Provide Added Data Analysis; Says No Specific Adverse Events Were Cited In DMC's Review,2019-11-25 07:13:00-05:00,CTSO,negative
314619.0,UPDATE: CytoSorbents Says Data Monitoring Committee Recommended Temporary Pause In Trial Enrollment As Co. Transitions To A New Contract Research Organization For Trial,2019-11-25 07:13:00-05:00,CTSO,positive
314620.0,CytoSorbents Reports Temporarily Pauses Enrollment In REFRESH 2-AKI Study,2019-11-25 07:11:00-05:00,CTSO,neutral
314621.0,"CytoSorbents Q3 EPS $(0.21) Beats $(0.22) Estimate, Sales $6.1M Miss $6.66M Estimate",2019-11-05 16:40:00-05:00,CTSO,negative
314622.0,CytoSorbents Reports Enrollment Of First Patient In TISORB Trial; Opens Operating Subsidiary In UK,2019-11-01 07:17:00-04:00,CTSO,neutral
314623.0,58 Biggest Movers From Friday,2019-10-14 03:51:00-04:00,CTSO,neutral
314624.0,50 Biggest Movers From Yesterday,2019-10-10 05:17:00-04:00,CTSO,neutral
314625.0,CytoSorbents Reports Removal Of Ticagrelor Intraoperatively Results In Expected Cost Savings Of ~$5K Per Patient,2019-10-04 07:16:00-04:00,CTSO,neutral
314626.0,CytoSorbents Awarded $2.96M Contract For K+ontrol Renal Support System For Reduction Of Hyperkalemia,2019-09-26 15:17:00-04:00,CTSO,positive
314627.0,CytoSorbents Highlights Survival Benefit Of CytoSorb Therapy In Septic Shock,2019-09-25 07:06:00-04:00,CTSO,positive
314628.0,75 Biggest Movers From Yesterday,2019-08-16 05:16:00-04:00,CTSO,neutral
314629.0,Cytosorbents Corporation Receives Renewal Of Its European Union Ce Mark Through May 2024 And Iso 13485:2016 Full Quality Assurance System Certification Of Its Manufacturing Facility Through September 2022,2019-08-15 13:56:00-04:00,CTSO,positive
314630.0,46 Stocks Moving In Thursday's Mid-Day Session,2019-08-15 12:44:00-04:00,CTSO,neutral
314631.0,"CytoSorbents Expands CytoSorb Distribution In Latin America To Brazil, Colombia, And Costa Rica",2019-08-13 07:09:00-04:00,CTSO,positive
314632.0,Stocks That Hit 52-Week Lows Of Monday,2019-08-12 11:14:00-04:00,CTSO,negative
314633.0,90 Biggest Movers From Yesterday,2019-08-08 05:17:00-04:00,CTSO,neutral
314634.0,"CytoSorbents Q2 EPS $(0.11) Beats $(0.14) Estimate, Sales $5.85M Miss $6.17M Estimate",2019-08-06 16:28:00-04:00,CTSO,negative
314635.0,95 Biggest Movers From Yesterday,2019-05-09 05:01:00-04:00,CTSO,neutral
314636.0,75 Stocks Moving In Wednesday's Mid-Day Session,2019-05-08 12:24:00-04:00,CTSO,neutral
314637.0,CytoSorbents shares are trading lower after the company reported mixed Q1 financial results.,2019-05-08 09:32:00-04:00,CTSO,neutral
314638.0,"Cytosorbents Q1 EPS $(0.15) Beats $(0.18) Estimate, Sales $5.19M Miss $6.17M Estimate",2019-05-07 17:09:00-04:00,CTSO,negative
314639.0,"CytoSorbents FY18 Sales $22.5M, Up From $15.2M YoY",2019-03-07 16:24:00-05:00,CTSO,neutral
314640.0,CytoSorbents Announces its Data Safety Monitoring Board Recommends Continuing its REMOVE Trial,2019-02-04 07:00:00-05:00,CTSO,positive
314641.0,CytoSorbents Expands its Distribution Agreement with Fresenius Medical Care to Include Korea and Mexico,2019-01-22 07:13:00-05:00,CTSO,positive
314642.0,40 Stocks Moving In Friday's Pre-Market Session,2019-01-18 08:07:00-05:00,CTSO,neutral
314643.0,"CytoSorbents Sees FY18 Sales OF At Least $22.3M vs $22.71M Est., Product Sales Of ~$20.2M",2019-01-07 09:23:00-05:00,CTSO,neutral
314644.0,CytoSorbents To Receive ~$620K In Non-Dilutive Funding From New Jersey Technology Business Tax Certificate Transfer Program,2018-12-21 08:45:00-05:00,CTSO,neutral
314645.0,88 Biggest Movers From Yesterday,2018-11-08 04:54:00-05:00,CTSO,neutral
314646.0,"Cytosorbents Q3 EPS $(0.10) Beats $(0.14) Estimate, Sales $5.743M Miss $5.88M Estimate",2018-11-06 17:22:00-05:00,CTSO,negative
314647.0,​​​​​​​CytoSorbents REFRESH 2-AKI Protocol Amendment Approved by FDA,2018-09-04 07:22:00-04:00,CTSO,positive
314648.0,​​​​​​​CytoSorbents REFRESH 2-AKI Protocol Amendment Approved by FDA,2018-09-04 07:22:00-04:00,CTSO,positive
314649.0,CytoSorbents REFRESH 2-AKI Protocol Amendment Approved by FDA,2018-09-04 07:16:00-04:00,CTSO,positive
314650.0,"Stocks Which Set New 52-Week High Yesterday, August 30th",2018-08-31 10:11:00-04:00,CTSO,neutral
314651.0,"Stocks Which Set New 52-Week High Yesterday, August 29th",2018-08-30 11:47:00-04:00,CTSO,neutral
314652.0,"The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex's Precision Medicine Collaboration",2018-08-30 08:02:00-04:00,CTSO,neutral
314653.0,"Stocks Which Set New 52-Week High Yesterday, August 28th",2018-08-29 11:13:00-04:00,CTSO,neutral
314654.0,"Stocks Which Set New 52-Week Highs Friday, August 3rd",2018-08-06 13:02:00-04:00,CTSO,neutral
314655.0,26 Stocks Moving In Monday's Pre-Market Session,2018-08-06 08:04:00-04:00,CTSO,neutral
314656.0,"Stocks Which Set New 52-Week High Yesterday, August 2nd",2018-08-03 11:16:00-04:00,CTSO,neutral
314657.0,"The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings",2018-08-03 07:52:00-04:00,CTSO,neutral
314658.0,"Cytosorbents Q2 EPS $(0.19) Misses $(0.12) Estimate, Sales $5.246M Beat $5.07M Estimate",2018-08-02 16:45:00-04:00,CTSO,negative
314659.0,CytoSorbents Reports Expanded Distribution Of CytoSorb To Total Of 53 Countries,2018-07-31 07:16:00-04:00,CTSO,neutral
314660.0,"Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering",2018-07-13 08:34:00-04:00,CTSO,neutral
314661.0,"Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug",2018-06-15 09:13:00-04:00,CTSO,neutral
314662.0,"Benzinga's Daily Biotech Pulse: Johnson & Johnson to Dispose Sterilization Products Business, Mixed Results From Protesostasis' Cystic Fibrosis Study",2018-06-07 07:58:00-04:00,CTSO,neutral
314663.0,"Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved",2018-05-18 08:00:00-04:00,CTSO,positive
314664.0,Cytosorbents Sees Q2 Sales To Exceed Sales In Q1,2018-05-08 16:28:00-04:00,CTSO,neutral
314665.0,"Cytosorbents Q1 EPS $(0.10) Beats $(0.12) Estimate, Sales $4.925M Beat $4.82M Estimate",2018-05-08 16:28:00-04:00,CTSO,neutral
314666.0,Cytosorbents Says They Expect Q2 Product Sales To Exceed Product Sales Reported In Q1,2018-05-08 16:18:00-04:00,CTSO,neutral
314667.0,Cytosorbents Q1 EPS $(0.10) Beats $(0.12) Estimate,2018-05-08 16:17:00-04:00,CTSO,neutral
314668.0,CytoSorbents Reports Enrollment Of First Patient In Pivotal US REFRESH 2-AKI Trial Using CytoSorb During Complex Cardiac Surgery,2018-04-24 07:09:00-04:00,CTSO,neutral
314669.0,41 Biggest Movers From Yesterday,2018-02-22 05:13:00-05:00,CTSO,neutral
314670.0,34 Stocks Moving In Wednesday's Mid-Day Session,2018-02-21 12:34:00-05:00,CTSO,neutral
314671.0,25 Stocks Moving In Wednesday's Pre-Market Session,2018-02-21 08:02:00-05:00,CTSO,neutral
314672.0,"CytoSorbents Announces Q4 Prelim. Sales $4.6M vs $4.19M Est., FY17 Sales $15M vs $14.8M Est.",2018-01-08 07:19:00-05:00,CTSO,neutral
314673.0,Cytosorbents Shares Up 3.82% Following Thurs. News Of FDA Approval For REFRESH 2 Medical Device,2017-12-22 10:54:00-05:00,CTSO,positive
314674.0,CytoSorbents Announces FDA Approval Of U.S. REFRESH 2 Pivotal Cardiac Surgery Trial IDE Application,2017-12-21 14:59:00-05:00,CTSO,positive
314675.0,CytoSorbents Receives $676K in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program,2017-12-19 07:06:00-05:00,CTSO,neutral
314676.0,"CytoSorbents Reports Q3 EPS $(0.07) vs. $(0.07) ESt., Sales $3.8M vs. $3.86M Est.",2017-11-09 16:19:00-05:00,CTSO,neutral
314677.0,CytoSorbents Awarded ~$1.0M in Phase II SBIR Funding to Optimize New Treatment Approaches for Severe Hyperkalemia,2017-11-01 07:10:00-04:00,CTSO,positive
314678.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-10-19 08:08:00-04:00,CTSO,neutral
314679.0,"CytoSorbents Up 8.6%, Strength Being Attributed To New Buy Recommendation From Agora Financial",2017-09-28 13:21:00-04:00,CTSO,positive
314680.0,CytoSorbents Wins $719K Grant to Develop Therapies to Stabilize Burn Victims,2017-08-14 07:19:00-04:00,CTSO,positive
314681.0,"CytoSorbents Reports Q2 Loss/Share $(0.04) vs. $(0.06) Est., Sales $3.6M vs. $3.42M Est.",2017-08-07 17:01:00-04:00,CTSO,neutral
314682.0,"CytoSorbents Increases Distribution, Sales of CytoSorb to treat Deadly Inflammation in Panama with DRGR",2017-07-17 09:19:00-04:00,CTSO,positive
314683.0,CytoSorbents Wins $1 Million STTR Phase II Contract To Advance Development of Life-Saving Universal Plasma,2017-07-13 07:09:00-04:00,CTSO,positive
314684.0,CytoSorbents Announces $5M of Debt Financing,2017-07-05 07:07:00-04:00,CTSO,negative
314685.0,15 Biggest Mid-Day Gainers For Wednesday,2017-06-07 12:45:00-04:00,CTSO,neutral
314686.0,"Benzinga's Top Upgrades, Downgrades For June 7, 2017",2017-06-07 09:27:00-04:00,CTSO,positive
314687.0,"Cowen & Co. Initiates Coverage On Cytosorbents with Outperform Rating, Announces $7.00 Price Target",2017-06-07 07:57:00-04:00,CTSO,neutral
314688.0,20 Biggest Mid-Day Losers For Tuesday,2017-05-09 12:32:00-04:00,CTSO,negative
314689.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-05-09 08:16:00-04:00,CTSO,neutral
314690.0,"CytoSorbents Reports Q1 EPS $(0.05) vs $(0.10) Est, Sales $2.59M vs $3.2M Est.",2017-05-08 16:39:00-04:00,CTSO,neutral
314691.0,CytoSorbents Reports REFRESH I Trial Results: Achieved the goals of this safety and feasibility study with demonstration of safe and significant reduction of toxic inflammatory mediators during complex open heart surgery,2017-05-05 09:02:00-04:00,CTSO,positive
314692.0,CytoSorbents Reports Winning of $1M Phase II SBIR Contract by Dept. of Defense for Advancement of Fungal Mycotoxin Blood Purification,2017-04-24 08:05:00-04:00,CTSO,positive
314693.0,15 Biggest Mid-Day Losers For Friday,2017-03-31 12:41:00-04:00,CTSO,negative
314694.0,18 Stocks Moving In Friday's Pre-Market Session,2017-03-31 08:26:00-04:00,CTSO,neutral
314695.0,CytoSorbents Prices Offering of ~2.22M Shares at $4.50/Share,2017-03-31 08:00:00-04:00,CTSO,positive
314696.0,CytoSorbents Reports Proposed Offering of Common Stock,2017-03-30 16:01:00-04:00,CTSO,neutral
314697.0,CytoSorbents Awarded Patent for Company's Base Polymer System,2017-03-28 07:18:00-04:00,CTSO,positive
314698.0,CytoSorbents Announces CytoSorb Partnership with Dr. Reddy's for S African Market,2017-03-16 07:13:00-04:00,CTSO,neutral
314699.0,"CytoSorbents Reports FY16 EPS $(0.47) vs $(0.33) in FY15, Sales $9.528M vs $4.79M YoY",2017-03-03 07:06:00-05:00,CTSO,neutral
314700.0,"Earnings Scheduled For March 3, 2017",2017-03-03 05:05:00-05:00,CTSO,neutral
314701.0,UPDATE: CytoSorbents Says is in the Process of Notifying FDA of Official Close of CytoSorb Study,2017-01-10 17:01:00-05:00,CTSO,neutral
314702.0,"8-K from CytoSorbents Shows Recent Amendments for CytoSorb Study Did Not Result in Increased Patient Enrollment; Co., US Air Force Determined to Close Study",2017-01-10 17:00:00-05:00,CTSO,positive
314703.0,Cytosorbents Sees FY2016 Sales $8.10M-8.30M vs $8.90M Est,2017-01-10 09:02:00-05:00,CTSO,neutral
314704.0,"Fresenius Medical Care, CytoSorbents Expand Original Partnership and Add New Co-Marketing Agreement for Worldwide CytoSorb Markets",2017-01-09 08:17:00-05:00,CTSO,positive
314705.0,Cytosorbents Shares Unchanged Following Co. Announcing First Sales Of New CytoSorb CPB Procedure Pack Earlier This Morning,2016-12-20 13:15:00-05:00,CTSO,positive
314706.0,"Cytosorbents Corp: Chan Phillip P. (Director, President and CEO) Buys 4,600 @ Avg Price: $5.40 (Form4",2016-12-13 13:11:00-05:00,CTSO,neutral
314707.0,"CytoSorb Reports Q3 Sales $2.41M vs $1.34M in Same Qtr. Last Year, EPS $(0.11), Unch on YoY Basis",2016-11-07 16:27:00-05:00,CTSO,neutral
314708.0,Cytosorbents Gets Bullish Commentary On European Outlook,2016-10-26 12:55:00-04:00,CTSO,neutral
314709.0,Benzinga's Top Initiations,2016-10-26 11:02:00-04:00,CTSO,positive
314710.0,"Aegis Capital Initiates Coverage On Cytosorbents Corporation - Common Stock at Buy, Announces $20.00",2016-10-26 05:51:00-04:00,CTSO,neutral
314711.0,"B. Riley Initiates Coverage on Cytosorbents at Buy, Announces $11.25 PT",2016-10-07 07:02:00-04:00,CTSO,neutral
314712.0,Mid-Afternoon Market Update: Dow Gains 125 Points; Net 1 Shares Spike Higher,2016-10-05 14:41:00-04:00,CTSO,positive
314713.0,12 Biggest Mid-Day Losers For Wednesday,2016-10-05 13:13:00-04:00,CTSO,negative
314714.0,CytoSorbents Reports Top-Line Safety Data from REFRESH I Cardiac Surgery Trial: to Demonstrate Safety of Intra-operative CytoSorb Use in High Risk Cardiac Surgery,2016-10-05 07:04:00-04:00,CTSO,positive
314715.0,"Brean Capital Assumes Cytosorbents at Buy, Announces $24.00 PT",2016-10-04 08:39:00-04:00,CTSO,neutral
314716.0,12 Biggest  Mid-Day  Gainers For Monday,2016-09-12 12:28:00-04:00,CTSO,neutral
314717.0,Mid-Day Market Update: American Farmland Gains Following Merger News; RetailMeNot Shares Drop,2016-09-12 12:15:00-04:00,CTSO,positive
314718.0,Mid-Morning Market Update: Markets Rise; Horizon Pharma To Buy Raptor Pharmaceutical For $9/Share,2016-09-12 10:31:00-04:00,CTSO,neutral
314719.0,"CEO Chan Buys 5,000 Shares Of CytoSorbents @$4.89/Share -Form 4",2016-08-26 11:02:00-04:00,CTSO,positive
314720.0,Here Are All The CEOs Benzinga Spoke With In 2016,2016-08-16 11:30:00-04:00,CTSO,neutral
314721.0,Exclusive: Cytosorbents CEO On How Its Blood Purification Technology Can Change Healthcare,2016-08-15 08:54:00-04:00,CTSO,positive
314722.0,"CytoSorbents Reports Q2 Loss ($0.19), Rev $4.03M",2016-08-09 16:29:00-04:00,CTSO,negative
314723.0,"CytoSorbents Awarded $150,000 Phase I STTR Contract for Universal Plasma Development",2016-06-22 09:03:00-04:00,CTSO,positive
314724.0,CytoSorbents Corp. Independent Data Safety Monitoring Board Suggests Continuation Of Trial Completion Without Changes,2016-05-27 08:02:00-04:00,CTSO,positive
314725.0,"Cytosorbents Corp Q1 EPS ($0.08) vs ($0.10) est, Revenue 1.60M vs $1.69M est",2016-05-09 17:07:00-04:00,CTSO,neutral
314726.0,CytoSorbents Reports Q4 Rev. $4M vs. Est. $1.58M,2016-03-09 16:16:00-05:00,CTSO,neutral
314727.0,Cytosorbents Gains 10% Following Encouraging Top Line Results,2016-02-26 13:58:00-05:00,CTSO,positive
314728.0,CytoSorb Investigator-Initiated Septic Shock Study Shows Encouraging Top Line Results,2016-02-26 07:07:00-05:00,CTSO,positive
314729.0,CytoSorbents Gives Update On EAP Application,2015-12-21 10:23:00-05:00,CTSO,neutral
314730.0,CytoSorbents Expands Distribution of CytoSorb to Vietnam In Multi-Year Distribution Agreement With Hoang Long Pharma,2015-12-15 07:03:00-05:00,CTSO,positive
314731.0,Option Alert: $CTSO Feb $10 Call Sweep; 500 Contracts @Ask @$0.30; Ref $6.64,2015-11-24 12:38:00-05:00,CTSO,positive
314732.0,Cytosorbents Corp Reports Q3 Revs $1.3M Vs Est $1.26M,2015-11-13 08:01:00-05:00,CTSO,neutral
314733.0,"Cytosorbents Corp Reports Q2 EPS $0.05 May Not Compare, Sales $946K Vs Est $910K",2015-08-13 16:18:00-04:00,CTSO,neutral
314734.0,Morning Market Losers,2015-05-11 09:57:00-04:00,CTSO,negative
314735.0,CytoSorbents Issues Letter to Shareholders,2015-04-24 08:01:00-04:00,CTSO,neutral
314736.0,Morning Market Losers,2015-04-01 09:53:00-04:00,CTSO,negative
314737.0,"CytoSorbents Reports FY14 Sales $4.1M, Net Loss $1.29/Share; Sees Q1 Sales ~45% YoY",2015-03-31 16:52:00-04:00,CTSO,negative
314738.0,MLV Initiates Coverage on Cytosorbents at Buy,2015-03-05 07:04:00-05:00,CTSO,neutral
314739.0,WBB Securities Initiates Coverage on Cytosorbents at Speculative Buy,2015-02-25 08:31:00-05:00,CTSO,positive
314740.0,CytoSorbents Submits IDE Application to FDA For U.S. CytoSorb Cardiac Surgery Trial,2014-12-30 07:15:00-05:00,CTSO,neutral
314741.0,CytoSorbents Awarded US Army SBIR Trauma Grant  ,2011-12-14 08:04:00-05:00,CTSO,positive
314742.0,CytoSorbents Awarded US Army SBIR Trauma Grant  ,2011-12-14 08:03:00-05:00,CTSO,positive
